报告题目🧑🏼‍🎓：Development of novel therapeutics based on antibody mimetics

报告人：Brian B. RUDKIN😲，法国CNRS教授

主持人：李晓涛 教授

报告时间😫：2017年6月5日 13:30-15:00

报告地点：闵行生科院534小会议室

主办单位：天美娱乐，科技处

 

报告人简介：Dr. Rudkin is a Research Director at the CNRS within the Stem Cell and Brain Research Institute (SBRI), Inserm U1208, University of Lyon and Co-Founder, in 2009, of the Joint Laboratory on Neuropathogenesis along with Prof. Chonggang YUAN at East China Normal University (ECNU) in Shanghai. Prior to joining the SBRI, he was Principal Investigator at the ENS Lyon, after being Senior Staff fellow at the National Institutes of Health (NICHD) USA, with G. Guroff (Nerve growth factor (NGF) signaling), subsequent to Post-Doctoral experience with G. Thomas (S6 Kinase) then J. Jiricny (G/T Mismatch binding proteins), at the Friedrich Miescher Institut of now NOVARTIS, Basel, Switzerland. His PhD is from the Department of BioChemistry & BioPhysics, University of Pennsylvania.

Dr. Rudkin has dissected pathways involved in NGF signaling. Notably, his team was first to describe those responsible for cell cycle phase-specific anti-mitogenic and differentiation responses. This led from the regulation of promoter function, to trafficking, fate and identification of partners of NGF receptors that impact upon the signaling outcome from lipid rafts. The focus of applied research in the laboratory has implemented the peptide aptamers to identify novel therapeutic molecules towards existing validated therapeutic targets and to identify and validate novel targets for therapeutic intervention with particular focus on signaling pathway(s) involved in cancer, neurodegenerative and infectious diseases.

 

报告摘要：While systems biology approaches analyzing the genome, proteome, interactome, metabolome, etc. are increasing our understanding of complex regulatory and metabolic networks, identification of key proteins that regulate cellular responses and underlying metabolism, remains crucial for furthering our understanding of normal cellular processes and pathological perturbations thereof. Antibody mimetics, called “Peptide aptamers”, conceived to conceptually resemble antibodies, are small combinatorial proteins with a constant scaffold presenting a variable region. Their use for the identification and validation of novel targets and discovery of novel therapeutics in vitro, in cellular models, and in vivo in animal models for human disease, will be discussed, underlining the challenge afforded by their "packaging" and "delivery".